Abstract
As mentioned in the comment, we provide correlative evidence relating neoadjuvant chemotherapy (NAC) to improve overall survival in patients with upper tract urothelial cancer (UTUC). We agree entirely that given recent evidence supporting use of adjuvant cisplatin-based therapy,1 there is a compelling argument to be made for NAC in high-grade UTUC, particularly given postoperative renal function decline following nephroureterectomy.2,3
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
